▶ 調査レポート

抗がん剤の世界市場(~2026年)

• 英文タイトル:Global Anti-Cancer Drug Market Insights and Forecast to 2026

QYResearchが調査・発行した産業分析レポートです。抗がん剤の世界市場(~2026年) / Global Anti-Cancer Drug Market Insights and Forecast to 2026 / MRC2-11QY02527資料のイメージです。• レポートコード:MRC2-11QY02527
• 出版社/出版日:QYResearch / 2020年11月20日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、146ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:医療、製薬
• 販売価格(消費税別)
  Single User¥577,200 (USD3,900)▷ お問い合わせ
  Multi User¥865,800 (USD5,850)▷ お問い合わせ
  Enterprise License¥1,154,400 (USD7,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料は抗がん剤のグローバル市場について調査・分析したレポートです。種類別(アバスチン、リツキサン、ハーセプチン、アリムタ)市場規模、用途別(病院、クリニック、在宅ケア)市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別抗がん剤の競争状況、市場シェア
・世界の抗がん剤市場:種類別市場規模 2015年-2020年(アバスチン、リツキサン、ハーセプチン、アリムタ)
・世界の抗がん剤市場:種類別市場規模予測 2021年-2026年(アバスチン、リツキサン、ハーセプチン、アリムタ)
・世界の抗がん剤市場:用途別市場規模 2015年-2020年(病院、クリニック、在宅ケア)
・世界の抗がん剤市場:用途別市場規模予測 2021年-2026年(病院、クリニック、在宅ケア)
・北米の抗がん剤市場分析:米国、カナダ
・ヨーロッパの抗がん剤市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの抗がん剤市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の抗がん剤市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの抗がん剤市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Merck、Bristol-Myers Squibb、Bayer、GlaxoSmithKline、Novartis、Sanofi、Pfizer、Amgen、Celgene Corporation、Ariad Pharmaceuticals、Eli Lilly、Hoffmann-La Roche Ltd.、AstraZeneca、Boehringer Ingelheim GmbH、Teva Pharmaceuticals
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Anticancer drug, also called antineoplastic drug, any drug that is effective in the treatment of malignant, or cancerous, disease. There are several major classes of anticancer drugs; these include alkylating agents, antimetabolites, natural products, and hormones.
China and India are expected to offer good opportunities an account of improvement in healthcare infrastructure. In Africa, industry is expected to drive at lower rate on account of lack of healthcare infrastructure, expensive medical services and lack of consumer awareness.
Central & South America is expected to drive at stable rates on account of costly medicines coupled with minimal awareness initiatives by regional government. Global market is also expected to have legal conflicts arising on account of patents which in turn are expected to negatively impact overall industry.

Market Analysis and Insights: Global Anti-Cancer Drug Market
The global Anti-Cancer Drug market size is projected to reach US$ 87630 million by 2026, from US$ 84270 million in 2020, at a CAGR of 3.7%% during 2021-2026.

Global Anti-Cancer Drug Scope and Market Size
Anti-Cancer Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Anti-Cancer Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Anti-Cancer Drug market is segmented into
Avastin
Rituxan
Herceptin
Alimta

Segment by Application, the Anti-Cancer Drug market is segmented into
Hospital
Clinic
Home Care

Regional and Country-level Analysis
The Anti-Cancer Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Anti-Cancer Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Anti-Cancer Drug Market Share Analysis
Anti-Cancer Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Anti-Cancer Drug business, the date to enter into the Anti-Cancer Drug market, Anti-Cancer Drug product introduction, recent developments, etc.

The major vendors covered:
Merck
Bristol-Myers Squibb
Bayer
GlaxoSmithKline
Novartis
Sanofi
Pfizer
Amgen
Celgene Corporation
Ariad Pharmaceuticals
Eli Lilly
Hoffmann-La Roche Ltd.
AstraZeneca
Boehringer Ingelheim GmbH
Teva Pharmaceuticals

レポート目次

1 Study Coverage
1.1 Anti-Cancer Drug Product Introduction
1.2 Market Segments
1.3 Key Anti-Cancer Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Anti-Cancer Drug Market Size Growth Rate by Type
1.4.2 Avastin
1.4.3 Rituxan
1.4.4 Herceptin
1.4.5 Alimta
1.5 Market by Application
1.5.1 Global Anti-Cancer Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Home Care
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Anti-Cancer Drug Market Size, Estimates and Forecasts
2.1.1 Global Anti-Cancer Drug Revenue 2015-2026
2.1.2 Global Anti-Cancer Drug Sales 2015-2026
2.2 Global Anti-Cancer Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Anti-Cancer Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Anti-Cancer Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Anti-Cancer Drug Competitor Landscape by Players
3.1 Anti-Cancer Drug Sales by Manufacturers
3.1.1 Anti-Cancer Drug Sales by Manufacturers (2015-2020)
3.1.2 Anti-Cancer Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Anti-Cancer Drug Revenue by Manufacturers
3.2.1 Anti-Cancer Drug Revenue by Manufacturers (2015-2020)
3.2.2 Anti-Cancer Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Anti-Cancer Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Anti-Cancer Drug Revenue in 2019
3.2.5 Global Anti-Cancer Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Anti-Cancer Drug Price by Manufacturers
3.4 Anti-Cancer Drug Manufacturing Base Distribution, Product Types
3.4.1 Anti-Cancer Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Anti-Cancer Drug Product Type
3.4.3 Date of International Manufacturers Enter into Anti-Cancer Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Anti-Cancer Drug Market Size by Type (2015-2020)
4.1.1 Global Anti-Cancer Drug Sales by Type (2015-2020)
4.1.2 Global Anti-Cancer Drug Revenue by Type (2015-2020)
4.1.3 Anti-Cancer Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Anti-Cancer Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Anti-Cancer Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Anti-Cancer Drug Revenue Forecast by Type (2021-2026)
4.2.3 Anti-Cancer Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Anti-Cancer Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Anti-Cancer Drug Market Size by Application (2015-2020)
5.1.1 Global Anti-Cancer Drug Sales by Application (2015-2020)
5.1.2 Global Anti-Cancer Drug Revenue by Application (2015-2020)
5.1.3 Anti-Cancer Drug Price by Application (2015-2020)
5.2 Anti-Cancer Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Anti-Cancer Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Anti-Cancer Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Anti-Cancer Drug Price Forecast by Application (2021-2026)

6 North America
6.1 North America Anti-Cancer Drug by Country
6.1.1 North America Anti-Cancer Drug Sales by Country
6.1.2 North America Anti-Cancer Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Anti-Cancer Drug Market Facts & Figures by Type
6.3 North America Anti-Cancer Drug Market Facts & Figures by Application

7 Europe
7.1 Europe Anti-Cancer Drug by Country
7.1.1 Europe Anti-Cancer Drug Sales by Country
7.1.2 Europe Anti-Cancer Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Anti-Cancer Drug Market Facts & Figures by Type
7.3 Europe Anti-Cancer Drug Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Anti-Cancer Drug by Region
8.1.1 Asia Pacific Anti-Cancer Drug Sales by Region
8.1.2 Asia Pacific Anti-Cancer Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Anti-Cancer Drug Market Facts & Figures by Type
8.3 Asia Pacific Anti-Cancer Drug Market Facts & Figures by Application

9 Latin America
9.1 Latin America Anti-Cancer Drug by Country
9.1.1 Latin America Anti-Cancer Drug Sales by Country
9.1.2 Latin America Anti-Cancer Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Anti-Cancer Drug Market Facts & Figures by Type
9.3 Central & South America Anti-Cancer Drug Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Anti-Cancer Drug by Country
10.1.1 Middle East and Africa Anti-Cancer Drug Sales by Country
10.1.2 Middle East and Africa Anti-Cancer Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Anti-Cancer Drug Market Facts & Figures by Type
10.3 Middle East and Africa Anti-Cancer Drug Market Facts & Figures by Application

11 Company Profiles
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Description and Business Overview
11.1.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Merck Anti-Cancer Drug Products Offered
11.1.5 Merck Related Developments
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Corporation Information
11.2.2 Bristol-Myers Squibb Description and Business Overview
11.2.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bristol-Myers Squibb Anti-Cancer Drug Products Offered
11.2.5 Bristol-Myers Squibb Related Developments
11.3 Bayer
11.3.1 Bayer Corporation Information
11.3.2 Bayer Description and Business Overview
11.3.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Bayer Anti-Cancer Drug Products Offered
11.3.5 Bayer Related Developments
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Corporation Information
11.4.2 GlaxoSmithKline Description and Business Overview
11.4.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.4.4 GlaxoSmithKline Anti-Cancer Drug Products Offered
11.4.5 GlaxoSmithKline Related Developments
11.5 Novartis
11.5.1 Novartis Corporation Information
11.5.2 Novartis Description and Business Overview
11.5.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Novartis Anti-Cancer Drug Products Offered
11.5.5 Novartis Related Developments
11.6 Sanofi
11.6.1 Sanofi Corporation Information
11.6.2 Sanofi Description and Business Overview
11.6.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Sanofi Anti-Cancer Drug Products Offered
11.6.5 Sanofi Related Developments
11.7 Pfizer
11.7.1 Pfizer Corporation Information
11.7.2 Pfizer Description and Business Overview
11.7.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Pfizer Anti-Cancer Drug Products Offered
11.7.5 Pfizer Related Developments
11.8 Amgen
11.8.1 Amgen Corporation Information
11.8.2 Amgen Description and Business Overview
11.8.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Amgen Anti-Cancer Drug Products Offered
11.8.5 Amgen Related Developments
11.9 Celgene Corporation
11.9.1 Celgene Corporation Corporation Information
11.9.2 Celgene Corporation Description and Business Overview
11.9.3 Celgene Corporation Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Celgene Corporation Anti-Cancer Drug Products Offered
11.9.5 Celgene Corporation Related Developments
11.10 Ariad Pharmaceuticals
11.10.1 Ariad Pharmaceuticals Corporation Information
11.10.2 Ariad Pharmaceuticals Description and Business Overview
11.10.3 Ariad Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Ariad Pharmaceuticals Anti-Cancer Drug Products Offered
11.10.5 Ariad Pharmaceuticals Related Developments
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Description and Business Overview
11.1.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Merck Anti-Cancer Drug Products Offered
11.1.5 Merck Related Developments
11.12 Hoffmann-La Roche Ltd.
11.12.1 Hoffmann-La Roche Ltd. Corporation Information
11.12.2 Hoffmann-La Roche Ltd. Description and Business Overview
11.12.3 Hoffmann-La Roche Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Hoffmann-La Roche Ltd. Products Offered
11.12.5 Hoffmann-La Roche Ltd. Related Developments
11.13 AstraZeneca
11.13.1 AstraZeneca Corporation Information
11.13.2 AstraZeneca Description and Business Overview
11.13.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.13.4 AstraZeneca Products Offered
11.13.5 AstraZeneca Related Developments
11.14 Boehringer Ingelheim GmbH
11.14.1 Boehringer Ingelheim GmbH Corporation Information
11.14.2 Boehringer Ingelheim GmbH Description and Business Overview
11.14.3 Boehringer Ingelheim GmbH Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Boehringer Ingelheim GmbH Products Offered
11.14.5 Boehringer Ingelheim GmbH Related Developments
11.15 Teva Pharmaceuticals
11.15.1 Teva Pharmaceuticals Corporation Information
11.15.2 Teva Pharmaceuticals Description and Business Overview
11.15.3 Teva Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Teva Pharmaceuticals Products Offered
11.15.5 Teva Pharmaceuticals Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Anti-Cancer Drug Market Estimates and Projections by Region
12.1.1 Global Anti-Cancer Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Anti-Cancer Drug Revenue Forecast by Regions 2021-2026
12.2 North America Anti-Cancer Drug Market Size Forecast (2021-2026)
12.2.1 North America: Anti-Cancer Drug Sales Forecast (2021-2026)
12.2.2 North America: Anti-Cancer Drug Revenue Forecast (2021-2026)
12.2.3 North America: Anti-Cancer Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Anti-Cancer Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Anti-Cancer Drug Sales Forecast (2021-2026)
12.3.2 Europe: Anti-Cancer Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Anti-Cancer Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Anti-Cancer Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Anti-Cancer Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Anti-Cancer Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Anti-Cancer Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Anti-Cancer Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Anti-Cancer Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Anti-Cancer Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Anti-Cancer Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Anti-Cancer Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Anti-Cancer Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Anti-Cancer Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Anti-Cancer Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Anti-Cancer Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Anti-Cancer Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Anti-Cancer Drug Market Segments
Table 2. Ranking of Global Top Anti-Cancer Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Anti-Cancer Drug Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Avastin
Table 5. Major Manufacturers of Rituxan
Table 6. Major Manufacturers of Herceptin
Table 7. Major Manufacturers of Alimta
Table 8. Global Anti-Cancer Drug Market Size Growth Rate by Application 2020-2026 (K Units)
Table 9. Global Anti-Cancer Drug Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 10. Global Anti-Cancer Drug Sales by Regions 2015-2020 (K Units)
Table 11. Global Anti-Cancer Drug Sales Market Share by Regions (2015-2020)
Table 12. Global Anti-Cancer Drug Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Anti-Cancer Drug Sales by Manufacturers (2015-2020) (K Units)
Table 14. Global Anti-Cancer Drug Sales Share by Manufacturers (2015-2020)
Table 15. Global Anti-Cancer Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Anti-Cancer Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Cancer Drug as of 2019)
Table 17. Anti-Cancer Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Anti-Cancer Drug Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Anti-Cancer Drug Price (2015-2020) (USD/Unit)
Table 20. Anti-Cancer Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Anti-Cancer Drug Product Type
Table 22. Date of International Manufacturers Enter into Anti-Cancer Drug Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Anti-Cancer Drug Sales by Type (2015-2020) (K Units)
Table 25. Global Anti-Cancer Drug Sales Share by Type (2015-2020)
Table 26. Global Anti-Cancer Drug Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Anti-Cancer Drug Revenue Share by Type (2015-2020)
Table 28. Anti-Cancer Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 29. Global Anti-Cancer Drug Sales by Application (2015-2020) (K Units)
Table 30. Global Anti-Cancer Drug Sales Share by Application (2015-2020)
Table 31. North America Anti-Cancer Drug Sales by Country (2015-2020) (K Units)
Table 32. North America Anti-Cancer Drug Sales Market Share by Country (2015-2020)
Table 33. North America Anti-Cancer Drug Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Anti-Cancer Drug Revenue Market Share by Country (2015-2020)
Table 35. North America Anti-Cancer Drug Sales by Type (2015-2020) (K Units)
Table 36. North America Anti-Cancer Drug Sales Market Share by Type (2015-2020)
Table 37. North America Anti-Cancer Drug Sales by Application (2015-2020) (K Units)
Table 38. North America Anti-Cancer Drug Sales Market Share by Application (2015-2020)
Table 39. Europe Anti-Cancer Drug Sales by Country (2015-2020) (K Units)
Table 40. Europe Anti-Cancer Drug Sales Market Share by Country (2015-2020)
Table 41. Europe Anti-Cancer Drug Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Anti-Cancer Drug Revenue Market Share by Country (2015-2020)
Table 43. Europe Anti-Cancer Drug Sales by Type (2015-2020) (K Units)
Table 44. Europe Anti-Cancer Drug Sales Market Share by Type (2015-2020)
Table 45. Europe Anti-Cancer Drug Sales by Application (2015-2020) (K Units)
Table 46. Europe Anti-Cancer Drug Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Anti-Cancer Drug Sales by Region (2015-2020) (K Units)
Table 48. Asia Pacific Anti-Cancer Drug Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Anti-Cancer Drug Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Anti-Cancer Drug Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Anti-Cancer Drug Sales by Type (2015-2020) (K Units)
Table 52. Asia Pacific Anti-Cancer Drug Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Anti-Cancer Drug Sales by Application (2015-2020) (K Units)
Table 54. Asia Pacific Anti-Cancer Drug Sales Market Share by Application (2015-2020)
Table 55. Latin America Anti-Cancer Drug Sales by Country (2015-2020) (K Units)
Table 56. Latin America Anti-Cancer Drug Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Anti-Cancer Drug Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Anti-Cancer Drug Revenue Market Share by Country (2015-2020)
Table 59. Latin America Anti-Cancer Drug Sales by Type (2015-2020) (K Units)
Table 60. Latin America Anti-Cancer Drug Sales Market Share by Type (2015-2020)
Table 61. Latin America Anti-Cancer Drug Sales by Application (2015-2020) (K Units)
Table 62. Latin America Anti-Cancer Drug Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Anti-Cancer Drug Sales by Country (2015-2020) (K Units)
Table 64. Middle East and Africa Anti-Cancer Drug Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Anti-Cancer Drug Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Anti-Cancer Drug Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Anti-Cancer Drug Sales by Type (2015-2020) (K Units)
Table 68. Middle East and Africa Anti-Cancer Drug Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Anti-Cancer Drug Sales by Application (2015-2020) (K Units)
Table 70. Middle East and Africa Anti-Cancer Drug Sales Market Share by Application (2015-2020)
Table 71. Merck Corporation Information
Table 72. Merck Description and Major Businesses
Table 73. Merck Anti-Cancer Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 74. Merck Product
Table 75. Merck Recent Development
Table 76. Bristol-Myers Squibb Corporation Information
Table 77. Bristol-Myers Squibb Description and Major Businesses
Table 78. Bristol-Myers Squibb Anti-Cancer Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 79. Bristol-Myers Squibb Product
Table 80. Bristol-Myers Squibb Recent Development
Table 81. Bayer Corporation Information
Table 82. Bayer Description and Major Businesses
Table 83. Bayer Anti-Cancer Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 84. Bayer Product
Table 85. Bayer Recent Development
Table 86. GlaxoSmithKline Corporation Information
Table 87. GlaxoSmithKline Description and Major Businesses
Table 88. GlaxoSmithKline Anti-Cancer Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 89. GlaxoSmithKline Product
Table 90. GlaxoSmithKline Recent Development
Table 91. Novartis Corporation Information
Table 92. Novartis Description and Major Businesses
Table 93. Novartis Anti-Cancer Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 94. Novartis Product
Table 95. Novartis Recent Development
Table 96. Sanofi Corporation Information
Table 97. Sanofi Description and Major Businesses
Table 98. Sanofi Anti-Cancer Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 99. Sanofi Product
Table 100. Sanofi Recent Development
Table 101. Pfizer Corporation Information
Table 102. Pfizer Description and Major Businesses
Table 103. Pfizer Anti-Cancer Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 104. Pfizer Product
Table 105. Pfizer Recent Development
Table 106. Amgen Corporation Information
Table 107. Amgen Description and Major Businesses
Table 108. Amgen Anti-Cancer Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 109. Amgen Product
Table 110. Amgen Recent Development
Table 111. Celgene Corporation Corporation Information
Table 112. Celgene Corporation Description and Major Businesses
Table 113. Celgene Corporation Anti-Cancer Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 114. Celgene Corporation Product
Table 115. Celgene Corporation Recent Development
Table 116. Ariad Pharmaceuticals Corporation Information
Table 117. Ariad Pharmaceuticals Description and Major Businesses
Table 118. Ariad Pharmaceuticals Anti-Cancer Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 119. Ariad Pharmaceuticals Product
Table 120. Ariad Pharmaceuticals Recent Development
Table 121. Eli Lilly Corporation Information
Table 122. Eli Lilly Description and Major Businesses
Table 123. Eli Lilly Anti-Cancer Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 124. Eli Lilly Product
Table 125. Eli Lilly Recent Development
Table 126. Hoffmann-La Roche Ltd. Corporation Information
Table 127. Hoffmann-La Roche Ltd. Description and Major Businesses
Table 128. Hoffmann-La Roche Ltd. Anti-Cancer Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 129. Hoffmann-La Roche Ltd. Product
Table 130. Hoffmann-La Roche Ltd. Recent Development
Table 131. AstraZeneca Corporation Information
Table 132. AstraZeneca Description and Major Businesses
Table 133. AstraZeneca Anti-Cancer Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 134. AstraZeneca Product
Table 135. AstraZeneca Recent Development
Table 136. Boehringer Ingelheim GmbH Corporation Information
Table 137. Boehringer Ingelheim GmbH Description and Major Businesses
Table 138. Boehringer Ingelheim GmbH Anti-Cancer Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 139. Boehringer Ingelheim GmbH Product
Table 140. Boehringer Ingelheim GmbH Recent Development
Table 141. Teva Pharmaceuticals Corporation Information
Table 142. Teva Pharmaceuticals Description and Major Businesses
Table 143. Teva Pharmaceuticals Anti-Cancer Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 144. Teva Pharmaceuticals Product
Table 145. Teva Pharmaceuticals Recent Development
Table 146. Global Anti-Cancer Drug Sales Forecast by Regions (2021-2026) (K Units)
Table 147. Global Anti-Cancer Drug Sales Market Share Forecast by Regions (2021-2026)
Table 148. Global Anti-Cancer Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 149. Global Anti-Cancer Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 150. North America: Anti-Cancer Drug Sales Forecast by Country (2021-2026) (K Units)
Table 151. North America: Anti-Cancer Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 152. Europe: Anti-Cancer Drug Sales Forecast by Country (2021-2026) (K Units)
Table 153. Europe: Anti-Cancer Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 154. Asia Pacific: Anti-Cancer Drug Sales Forecast by Region (2021-2026) (K Units)
Table 155. Asia Pacific: Anti-Cancer Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 156. Latin America: Anti-Cancer Drug Sales Forecast by Country (2021-2026) (K Units)
Table 157. Latin America: Anti-Cancer Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 158. Middle East and Africa: Anti-Cancer Drug Sales Forecast by Country (2021-2026) (K Units)
Table 159. Middle East and Africa: Anti-Cancer Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 160. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 161. Key Challenges
Table 162. Market Risks
Table 163. Main Points Interviewed from Key Anti-Cancer Drug Players
Table 164. Anti-Cancer Drug Customers List
Table 165. Anti-Cancer Drug Distributors List
Table 166. Research Programs/Design for This Report
Table 167. Key Data Information from Secondary Sources
Table 168. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Cancer Drug Product Picture
Figure 2. Global Anti-Cancer Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Avastin Product Picture
Figure 4. Rituxan Product Picture
Figure 5. Herceptin Product Picture
Figure 6. Alimta Product Picture
Figure 7. Global Anti-Cancer Drug Sales Market Share by Application in 2020 & 2026
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Home Care
Figure 11. Anti-Cancer Drug Report Years Considered
Figure 12. Global Anti-Cancer Drug Market Size 2015-2026 (US$ Million)
Figure 13. Global Anti-Cancer Drug Sales 2015-2026 (K Units)
Figure 14. Global Anti-Cancer Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Anti-Cancer Drug Sales Market Share by Region (2015-2020)
Figure 16. Global Anti-Cancer Drug Sales Market Share by Region in 2019
Figure 17. Global Anti-Cancer Drug Revenue Market Share by Region (2015-2020)
Figure 18. Global Anti-Cancer Drug Revenue Market Share by Region in 2019
Figure 19. Global Anti-Cancer Drug Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Anti-Cancer Drug Revenue in 2019
Figure 21. Anti-Cancer Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Anti-Cancer Drug Sales Market Share by Type (2015-2020)
Figure 23. Global Anti-Cancer Drug Sales Market Share by Type in 2019
Figure 24. Global Anti-Cancer Drug Revenue Market Share by Type (2015-2020)
Figure 25. Global Anti-Cancer Drug Revenue Market Share by Type in 2019
Figure 26. Global Anti-Cancer Drug Market Share by Price Range (2015-2020)
Figure 27. Global Anti-Cancer Drug Sales Market Share by Application (2015-2020)
Figure 28. Global Anti-Cancer Drug Sales Market Share by Application in 2019
Figure 29. Global Anti-Cancer Drug Revenue Market Share by Application (2015-2020)
Figure 30. Global Anti-Cancer Drug Revenue Market Share by Application in 2019
Figure 31. North America Anti-Cancer Drug Sales Growth Rate 2015-2020 (K Units)
Figure 32. North America Anti-Cancer Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Anti-Cancer Drug Sales Market Share by Country in 2019
Figure 34. North America Anti-Cancer Drug Revenue Market Share by Country in 2019
Figure 35. U.S. Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 36. U.S. Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 38. Canada Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Anti-Cancer Drug Market Share by Type in 2019
Figure 40. North America Anti-Cancer Drug Market Share by Application in 2019
Figure 41. Europe Anti-Cancer Drug Sales Growth Rate 2015-2020 (K Units)
Figure 42. Europe Anti-Cancer Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Anti-Cancer Drug Sales Market Share by Country in 2019
Figure 44. Europe Anti-Cancer Drug Revenue Market Share by Country in 2019
Figure 45. Germany Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 46. Germany Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 48. France Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 50. U.K. Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 52. Italy Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 54. Russia Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Anti-Cancer Drug Market Share by Type in 2019
Figure 56. Europe Anti-Cancer Drug Market Share by Application in 2019
Figure 57. Asia Pacific Anti-Cancer Drug Sales Growth Rate 2015-2020 (K Units)
Figure 58. Asia Pacific Anti-Cancer Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Anti-Cancer Drug Sales Market Share by Region in 2019
Figure 60. Asia Pacific Anti-Cancer Drug Revenue Market Share by Region in 2019
Figure 61. China Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 62. China Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 64. Japan Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 66. South Korea Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 68. India Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 70. Australia Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 72. Taiwan Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 74. Indonesia Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 76. Thailand Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 78. Malaysia Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 80. Philippines Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 82. Vietnam Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Anti-Cancer Drug Market Share by Type in 2019
Figure 84. Asia Pacific Anti-Cancer Drug Market Share by Application in 2019
Figure 85. Latin America Anti-Cancer Drug Sales Growth Rate 2015-2020 (K Units)
Figure 86. Latin America Anti-Cancer Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Anti-Cancer Drug Sales Market Share by Country in 2019
Figure 88. Latin America Anti-Cancer Drug Revenue Market Share by Country in 2019
Figure 89. Mexico Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 90. Mexico Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 92. Brazil Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 94. Argentina Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Anti-Cancer Drug Market Share by Type in 2019
Figure 96. Latin America Anti-Cancer Drug Market Share by Application in 2019
Figure 97. Middle East and Africa Anti-Cancer Drug Sales Growth Rate 2015-2020 (K Units)
Figure 98. Middle East and Africa Anti-Cancer Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Anti-Cancer Drug Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Anti-Cancer Drug Revenue Market Share by Country in 2019
Figure 101. Turkey Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 102. Turkey Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 104. Saudi Arabia Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Anti-Cancer Drug Sales Growth Rate (2015-2020) (K Units)
Figure 106. U.A.E Anti-Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Anti-Cancer Drug Market Share by Type in 2019
Figure 108. Middle East and Africa Anti-Cancer Drug Market Share by Application in 2019
Figure 109. North America Anti-Cancer Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 110. North America Anti-Cancer Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Anti-Cancer Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 112. Europe Anti-Cancer Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Anti-Cancer Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 114. Asia Pacific Anti-Cancer Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Anti-Cancer Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 116. Latin America Anti-Cancer Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Anti-Cancer Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 118. Middle East and Africa Anti-Cancer Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed